Lantern Pharma (LTRN) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Lantern Pharma (LTRN) is set to announce its Q2 2025 earnings on August 14th, with analysts predicting a loss of ($0.53) per share.
• In its previous earnings report on May 15th, Lantern Pharma posted a loss of ($0.42) EPS, exceeding expectations by $0.07.
• Insiders have sold a total of 315,700 shares valued over $1 million in the last quarter, indicating a significant reduction in their ownership positions.

Lantern Pharma (NASDAQ:LTRN - Get Free Report) is expected to be announcing its Q2 2025 earnings results before the market opens on Thursday, August 14th. Analysts expect the company to announce earnings of ($0.53) per share for the quarter.

Lantern Pharma (NASDAQ:LTRN - Get Free Report) last posted its quarterly earnings results on Thursday, May 15th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.07. During the same period in the prior year, the business earned ($0.51) EPS. On average, analysts expect Lantern Pharma to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Lantern Pharma Stock Down 1.2%

Shares of NASDAQ LTRN opened at $5.14 on Thursday. The firm's fifty day moving average is $3.62 and its 200 day moving average is $3.78. Lantern Pharma has a 52 week low of $2.55 and a 52 week high of $6.12. The company has a market cap of $55.41 million, a price-to-earnings ratio of -2.79 and a beta of 1.60.

Insider Transactions at Lantern Pharma

In other news, major shareholder Leslie W. Kreis sold 40,000 shares of the firm's stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $3.09, for a total value of $123,600.00. Following the completion of the sale, the insider directly owned 49,957 shares of the company's stock, valued at approximately $154,367.13. This trade represents a 44.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Aaron G.L. Fletcher sold 40,000 shares of the business's stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $3.09, for a total transaction of $123,600.00. Following the transaction, the insider owned 49,957 shares in the company, valued at $154,367.13. This represents a 44.47% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 315,700 shares of company stock valued at $1,000,580. 7.31% of the stock is currently owned by company insiders.

About Lantern Pharma

Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.